Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Equity Average (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 12 years of Equity Average data on record, last reported at $767.1 million in Q3 2025.

  • For Q3 2025, Equity Average rose 6.47% year-over-year to $767.1 million; the TTM value through Sep 2025 reached $767.1 million, up 6.47%, while the annual FY2024 figure was $685.9 million, 17.43% up from the prior year.
  • Equity Average reached $767.1 million in Q3 2025 per AMPH's latest filing, up from $754.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $767.1 million in Q3 2025 and bottomed at $437.8 million in Q4 2021.
  • Average Equity Average over 5 years is $586.6 million, with a median of $568.9 million recorded in 2023.
  • Peak YoY movement for Equity Average: fell 2.67% in 2021, then increased 21.79% in 2024.
  • A 5-year view of Equity Average shows it stood at $437.8 million in 2021, then increased by 18.06% to $516.9 million in 2022, then rose by 19.42% to $617.3 million in 2023, then grew by 18.26% to $730.0 million in 2024, then grew by 5.09% to $767.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $767.1 million in Q3 2025, $754.4 million in Q2 2025, and $741.8 million in Q1 2025.